Abstract

There is provided peptidic compounds of Formula I, A or B(Rradn6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa9-NH2). Xaa1 is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2 is Asn, Gln, Hse, Cit or His. Xaa3 is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4 is Ala or Ser. Xaa5 is Val, Cpg, or Tle. Xaa6 is Gly, NMe-Gly, or D-Ala. Xaa7 is His or NMe-His. Xaa8 is Leu or Phe. Xaa9-NH2 is a C-terminally amidated amino acid residue selected from Pro, 4-oxa-L-Pro, Me2 Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8 to Xaa9. Rradn6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins

Abstract

Provided herein is a compound having a structure of Formula (I): (Formula (I)) wherein: D is S, O or an ester; p is 1 to 6; L1 and/or L2 are independently linear or branched C1-C30 alkyl, optionally having one or more C═C double bonds of E or Z geometry; and wherein: if D is S then L1 and/or L2 are unsubstituted or substituted with one or more S; and if D is O or an ester, then L1 and/or L2 are substituted with one more S. The compound may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid. Further provided are methods for making the compound. Provided herein is a compound having a structure of Formula (I): (Formula (I)) wherein: D is S, O or an ester; p is 1 to 6; L1 and/or L2 are independently linear or branched C1-C30 alkyl, optionally having one or more C═C double bonds of E or Z geometry; and wherein: if D is S then L1 and/or L2 are unsubstituted or substituted with one or more S; and if D is O or an ester, then L1 and/or L2 are substituted with one more S. The compound may be formulated in a lipid nanoparticle for use in the delivery of charged cargo such as nucleic acid. Further provided are methods for making the compound.

IPC Classes  ?

• C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
• A61K 9/127 - Liposomes
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

A method for fabricating a micro-fabricated device comprising a cavity-defining surface which defines a cavity, comprises: fabricating a channel that provides fluid communication with the cavity, the channel comprising a Tesla valve for permitting fluid flow in a first direction out of the cavity and through the channel while impeding fluid flow through the channel into the cavity in a second direction opposed to the first direction; and applying a sealing material to the device to thereby seal the channel, wherein applying the sealing material comprises: introducing the sealing material to the channel; and depositing the sealing material onto one or more channel-defining surfaces. The sealing material is prevented from reaching the cavity at least in part by the action of the Tesla valve.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• B81B 3/00 - Devices comprising flexible or deformable elements, e.g. comprising elastic tongues or membranes

Abstract

This invention provides compound having a structure of Formulas I-VI. Uses of such compounds for treatment of various indications that would benefit from modulation of the androgen receptor, including prostate cancer. Also provided are methods of treatment and uses of the compounds described by Formulas I-VI.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/433 - Thiadiazoles
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 5/28 - Antiandrogens
• A61P 35/00 - Antineoplastic agents
• C07C 233/22 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
• C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• C07D 207/12 - Oxygen or sulfur atoms
• C07D 207/20 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• C07D 211/48 - Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 277/28 - Radicals substituted by nitrogen atoms
• C07D 307/84 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• C07D 333/54 - Benzo [b] thiophenes; Hydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems
• C07F 3/00 - Compounds containing elements of Groups 2 or 12 of the Periodic System
• C07F 11/00 - Compounds containing elements of Groups 6 or 16 of the Periodic System

Abstract

Apparatuses and methods for producing hydrogen peroxide by performing coupled chemical and electrochemical reactions are disclosed. An electrochemical cell has a chemical reaction chamber configured to hydrogenate amyl-anthraquinone (AAQ) and an electrochemical chamber configured to electrochemically dissociate water to form hydrogen ions at an anode, and to reduce the hydrogen ions to atomic hydrogen at a cathode. The chemical reaction chamber and the anode chamber are separated by a metallic membrane. The metallic membrane acts as a cathode of the cell, a hydrogen-selective layer and a catalyst. The metallic membrane may comprise a layer of palladium or a palladium alloy. A layer of co-catalyst may optionally be electrodeposited on the layer of palladium or palladium alloy. An ion exchange membrane separates the metallic membrane and the anode chamber. The hydrogenated AAQ may be supplied to a reactor for contacting an oxygen-containing gas to yield hydrogen peroxide.

IPC Classes  ?

• C01B 15/023 - Preparation from organic compounds by the alkyl-anthraquinone process

Abstract

The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

IPC Classes  ?

• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents
• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

Provided herein are methods for treating or preventing infection of a subject by a virus that infects the subject through angiotensin converting enzyme 2.

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present disclosure relates to cytochrome P450 monooxygenases capable of oxidizing a monoterpenoid indole alkaloid (MIA) substrate and methods and uses thereof. The substrate may be a camptothecinoid, an evodiaminoid or an ellipticinoid. The disclosure further relates to method of producing hydroxylated monoterpenoid indole alkaloids, as well as derivatives and analogues of the produced hydroxylated monoterpenoid indole alkaloids. Pharmaceutical compositions comprising the hydroxylated monoterpenoid indole alkaloid derivatives are also provided.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 35/00 - Antineoplastic agents
• C12P 17/18 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin

Abstract

The current invention features a rod screw for medical application that can be configured and used to fixate fracture of bones varying in shape and dimension, and treating maladies such as scoliosis, and securing an implanted device, to tissue such as bone. This is achieved by designing a flexible rod screw with a mechanism to lock the configuration in a rigid state. In an embodiment, a bone-fracture fixation device, such as a rod screw, includes a flexible body, a plurality of flexible members, and first and second interfaces. The flexible members are disposed longitudinally within the flexible body, such that the flexible body is rigid when the flexible members are fixed into position. And the first and second interfaces are respectively coupled to the flexible body, each of at least one of the first and second interfaces including a respective at least one hole each configured to receive a respective attachment member configured to engage a bone.

IPC Classes  ?

• A61B 17/74 - Devices for the head of the femur
• A61B 17/70 - Spinal positioners or stabilisers
• A61B 17/72 - Intramedullary devices

Abstract

Microparticle compositions comprising dietary fibers are disclosed. The microparticle compositions comprise a plurality of dietary fibers. In some embodiments, the plurality of dietary fibers comprise one or more hydrocolloids and one or more viscous fibers. In some embodiments, the one or more viscous fibers comprise a first viscous fiber and a second viscous fiber. The first viscous fiber may comprise a thickening agent. The first viscous fiber may comprise a bulking agent. In some embodiments, the plurality of dietary fibers further comprises one or more prebiotic fibers. One non-limiting example microparticle composition comprises chia mucilage, konjac glucomannan, psyllium husk, and inulin. Methods of making and method of use of the microparticle compositions are also disclosed.

IPC Classes  ?

• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A23L 29/00 - Foods or foodstuffs containing additives; Preparation or treatment thereof
• A23P 10/20 - Agglomerating; Granulating; Tabletting

Abstract

This application relates to amatoxin analogs in which the trans-4-substituent on the proline residue of the amatoxin is an R group other than a hydroxy, constructs comprising such amatoxin analogs coupled to a linker and conjugates comprising such amatoxin analog-linker constructs conjugated to a target moiety. The application also relates to uses of such amatoxin analogs, for example, in treatment of cancer. The analog is a compound of Formula I, wherein R1 is not OH:

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 35/00 - Antineoplastic agents
• C07K 7/64 - Cyclic peptides containing only normal peptide links

Abstract

Methods and apparatuses for converting carbon dioxide to useful compounds are disclosed. The method involves reducing bicarbonate solution in an electrolyzer. Bicarbonate solution is supplied to the cathode. The direct reduction of bicarbonate at the cathode may be coupled with an oxidation reaction at the anode. The oxidation reaction may provide a source of protons (H+) to cathode for the reduction of bicarbonate. The oxidation reaction may be a hydrogen oxidation reaction (HOR). Hydrogen gas (H2) may be supplied to the anode. In some embodiments, a source of gas may be supplied to the bicarbonate solution to form a pressurized solution before supplying the solution to the cathode.

IPC Classes  ?

• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 1/02 - Hydrogen or oxygen
• C25B 3/07 - Oxygen containing compounds
• C25B 3/26 - Reduction of carbon dioxide
• C25B 11/032 - Gas diffusion electrodes
• C25B 11/065 - Carbon
• C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
• C25B 15/08 - Supplying or removing reactants or electrolytes; Regeneration of electrolytes

Abstract

Capacitive micromachined ultrasonic transducers (CMUTs) may be fabricated on pre- fabricated and interconnected substrates, such as printed circuit boards (PCBs). The PCBs may be rigid or flexible. The substrate may also be a ceramic. The CMUTs may be polymer-based or silicon-based. Arrays of CMUTs may also be manufactured, with an array being made of CMUT elements, and with each CMUT element being made of individual CMUT cells. CMUT elements on a substrate such as a PCB may be respectively electrically connected to electrically interconnects (vias), allowing selective control of individual elements. The CMUTs may be manufactured through various depositions, patterning, and etching away of materials on the substrate, with the solvents used for etching being selected to be chemically compatible with the substrate and the other materials deposited on the substrate.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• B81B 3/00 - Devices comprising flexible or deformable elements, e.g. comprising elastic tongues or membranes
• H04R 1/00 - LOUDSPEAKERS, MICROPHONES, GRAMOPHONE PICK-UPS OR LIKE ACOUSTIC ELECTROMECHANICAL TRANSDUCERS; DEAF-AID SETS; PUBLIC ADDRESS SYSTEMS - Details of transducers
• H05K 1/18 - Printed circuits structurally associated with non-printed electric components

Abstract

This invention provides chronic graft-versus-host disease (cGVHD) biomarker panels for use in diagnostic and risk assignment methods. More particularly, the invention relates to particular combinations of biomarkers for diagnosing cGVHD and for predicting whether there is a low, intermediate or high risk of developing cGVHD. Furthermore, there are provided different treatment options depending on a patient's risk level or whether they have moderate to severe cGVHD.

IPC Classes  ?

• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• C40B 30/00 - Methods of screening libraries
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/483 - Physical analysis of biological material
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

The present invention relates to a novel anti-HLA-A2 antibody, and to a chimeric antigen receptor comprising said HLA-A2 antibody. The present invention further relates to an immune cell expressing said chimeric receptor antigen, and to therapeutic uses thereof, in particular for treating or preventing graft rejection or GVHD.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/725 - T-cell receptors

Abstract

The present invention relates to biomarker-based analyses for the stratification of Huntington Disease (HD) in a subject. The invention further relates to protein biomarkers (and particular combinations) and their use in monitoring biochemical changes in HD patients indicative of the stage, severity, progression, or age-of-onset of disease; guidance for the design of clinical trials; for selecting a therapeutic regimen and monitoring response to treatment. The invention further comprises methods for the detection of HD biomarkers in cerebrospinal fluid (CSF) and other biofluids in patients with HD or at risk of developing HD.

IPC Classes  ?

• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/487 - Physical analysis of biological material of liquid biological material
• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

Provided herein are pharmaceutical dosage forms for delivering peptide therapeutics to a mucosal surface. The pharmaceutical dosage forms comprise a mucoadhesive layer; a peptide loading layer; and a water impermeable layer, wherein the peptide loading layer is between the mucoadhesive layer and the water impermeable layer, such that the water impermeable layer facilitates unidirectional movement of the an encapsulated peptide through the mucoadhesive layer and to the target mucosal surface. The pharmaceutical dosage form is suitable for delivery of the encapsulated peptide therapeutic to buccal mucosa; sublingual mucosa; palate mucosa; and tongue mucosa. The peptide therapeutic may be an insulin; an insulin derivative; an insulin analog; a pre-insulin; a pro-drug of insulin; a glucagon-like peptide 1 (GLP-1); a GLP-1 analog; a pre- GLP-1; a pro-drug of GLP- 1; or a combination thereof and may be suitable for the treatment of diabetes.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/50 - Microcapsules
• A61K 38/28 - Insulins
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - Cellulose; Derivatives thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07K 14/62 - Insulins
• C07K 14/605 - Glucagons

Abstract

A photonic device configured to perform matrix vector multiplication operations at high frequencies is provided. The vector being multiplied by the matrix is defined by vector components at specific wavelengths. The device includes a first waveguide and a second waveguide. A series of tunable microring resonators (MRRs) are coupled to the first waveguide and to a respective series of passive delay rings (PDRs), which are coupled to the second waveguide. Each MRR/PDR pair defines a tunable matrix component (tunable weight) for a respective wavelength component of the vector. A series of controllable delay elements (CDEs) such as all-pass filters are coupled to the first waveguide, upstream from the tunable MRRs. Any tuning dependent group delay caused by the MRR/PDR pairs can be compensated by controlling the CDEs such that each wavelength components has substantially a same delay as the other wavelength components.

IPC Classes  ?

• G06E 3/00 - Devices not provided for in group , e.g. for processing analogue or hybrid data
• G02B 5/20 - Filters
• G02B 6/12 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind

Abstract

A method of combinatorial material screening comprising causing first and second precursors to travel through a mixing channel to form a first mixture, depositing the first mixture onto a substrate to form a first thin film in a first pattern, causing more of the first and second precursors to travel through the mixing channel to form a second mixture, depositing the second mixture onto the substrate to form a second thin film in a second pattern comparing one or more characteristics of the first and second thin films.

IPC Classes  ?

• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• C23C 14/24 - Vacuum evaporation
• C23C 14/58 - After-treatment

Abstract

The present disclosure relates to prostate specific membrane antigen (PSMA)-targeting compounds of formula (I) or of a salt or a solvate thereof. The PSMA-targeting compounds of the present disclosure can be useful as imaging agents for PSMA-expressing diseases/conditions.

IPC Classes  ?

• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• A61K 51/08 - Peptides, e.g. proteins

Abstract

The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C07K 14/28 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)

Abstract

The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.

IPC Classes  ?

• C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
• C07C 235/78 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
• A61K 51/04 - Organic compounds

Abstract

A UV reactor irradiates a flow of fluid with UV radiation. The reactor comprises: a fluid conduit defined by a heat conducting conduit body comprising one or more heat conducting walls for permitting a flow of fluid therethrough; a UV-LED operatively connected to a PCB and oriented for directing radiation into the fluid conduit. The PCB comprises a heat conducting substrate having a first surface. The conduit body is in thermal contact with the first surface of the heat conducting substrate. Heat is dissipated from the UV-LED via the heat conducting substrate, the thermal contact between the first surface of the heat conducting substrate and the heat conducting conduit body, and from the one or more heat conducting walls of the heat conducting conduit body to the fluid flowing through the fluid conduit.

IPC Classes  ?

• C02F 1/32 - Treatment of water, waste water, or sewage by irradiation with ultraviolet light
• H05K 1/02 - Printed circuits - Details
• H05K 1/18 - Printed circuits structurally associated with non-printed electric components
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

The present disclosure includes lignocellulosic foams which may be used, for example, in insulation as well as methods for their preparation. For example, the methods of preparing a foam may comprise: foaming an aqueous suspension comprising microfibrillated lignocellulose and a foaming agent to obtain a wet foam; and drying the wet foam to obtain the foam.

IPC Classes  ?

• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• B29C 44/20 - Shaping by internal pressure generated in the material, e.g. swelling or foaming for articles of indefinite length
• C08L 97/02 - Lignocellulosic material, e.g. wood, straw or bagasse

Abstract

Methods, systems, and techniques for the high speed manufacture of micro-electrical mechanical systems (MEMS) arrays, such as arrays of polymeric capacitive micromachined ultrasonic transducers (CMUTs). A sheet of material from which to form cavities for the devices is obtained, and physical or energy projections are projected into the material to form the cavities. Upper and lower surfaces of the material are respectively contacted with and bonded to upper and lower metalized films. The metalized portions of the upper and lower metalized films may serve as electrodes for a CMUT, and the films themselves may be the CMUT's substrate and membrane.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate

Abstract

A photonic device configured to perform matrix vector multiplication operations at high frequencies is provided. The vector being multiplied by the matrix is defined by vector components at specific wavelengths. The device includes a first waveguide and a second waveguide. A series of tunable microring resonators (MRRs) are coupled to the first waveguide and to a respective series of passive delay rings (PDRs), which are coupled to the second waveguide. Each MRR/PDR pair defines a tunable matrix component (tunable weight) for a respective wavelength component of the vector. A series of controllable delay elements (CDEs) such as all-pass filters are coupled to the first waveguide, upstream from the tunable MRRs. Any tuning dependent group delay caused by the MRR/PDR pairs can be compensated by controlling the CDEs such that each wavelength components has substantially a same delay as the other wavelength components.

IPC Classes  ?

• G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
• H04J 14/02 - Wavelength-division multiplex systems
• G06E 3/00 - Devices not provided for in group , e.g. for processing analogue or hybrid data

Abstract

The present invention provides a multiple lamellar vesicle active pharmaceutical ingredient (MLV-API) drug formulation comprising MLV in aqueous basic solution wherein the MLV encapsulates the API and wherein the API comprises a weak base compound. The MLV-API is prepared without the use of extrusion or dialysis procedures and is able to achieve high encapsulation efficiency of 90% as well as high drug to lipid ratio of over 15% by weight percentage. The present invention also provides a method as well as a kit for preparation of the MLV-API drug formulation.

IPC Classes  ?

• A61K 9/127 - Liposomes
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to anti-nociceptive compounds and uses thereof. In some embodiments, the present invention provides LEU-ENK analogues for treating pain, anxiety, mood disorders or depression.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61P 25/24 - Antidepressants
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

The present disclosure relates to methods of preparing protein hydrogels and to protein hydrogels which may, for example, be prepared from such methods. The methods comprise denaturing a protein in an aqueous environment to produce an aqueous composition comprising overlapping polypeptide chains; crosslinking the polypeptide chains to produce a denatured protein hydrogel comprising a crosslinked network of entangled polypeptide chains; and optionally at least partially renaturing the denatured protein hydrogel.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/22 - Polypeptides or derivatives thereof

Abstract

This invention provides combinations of kynurenine and antigen presenting cells (APC) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (T1D) or alopecia areata (AA). Uses of kynurenine and antigen presenting cells (APC) as an immune modulator for the treatment of T1D or AA are also provided.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61K 35/33 - Fibroblasts

Abstract

The present invention relates to methods of immune modulation. In particular, the present invention relates to regulation of neuroinflammation by modulation of ABCF1. Modulation of ABCF1 may be useful in the MDD.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/24 - Antidepressants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

An electrostatic capacity sensor 1 capable of expanding a force detectable region includes an upper electrode 11, a lower electrode 11 for detecting electrostatic capacity C between the lower electrode 11 and the upper electrode 11, and a base material 12 having dielectric properties and elasticity and disposed between upper and lower electrodes 11 and 11. An upper base material layer portion 12a and a lower base material layer portion 12b of the base material 12 are configured such that elastic deformation amounts when the same force is applied are different from each other.

IPC Classes  ?

• G01L 1/14 - Measuring force or stress, in general by measuring variations in capacitance or inductance of electrical elements, e.g. by measuring variations of frequency of electrical oscillators
• G01L 1/20 - Measuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress

Abstract

A method for producing a polymeric material is disclosed. The method combines blending of fibers and treating the fibers with a basic aqueous solution. In some embodiments, the blending of the fibers is performed at a blending speed sufficient to shear the fibers in one or both of a longitudinal direction and lateral direction of the fibers. In some embodiments, one or both of the blending and treating are performed in a sub-zero temperature, at a temperature of less than 0oC, or in a range of from about 0oC to about -20oC. One example application of the method is in the making of a cellulose film from wood pulp.

IPC Classes  ?

• C08L 1/02 - Cellulose; Modified cellulose
• B29B 15/08 - Pretreatment of the material to be shaped, not covered by groups of reinforcements or fillers
• C08J 5/18 - Manufacture of films or sheets

Abstract

Processes are provided for treating mineralized silicates by selective leaching of Ni and Co values carried out in concert with sequestration of gaseous CO2 as mineral carbonates. These processes may be applied to extract Ni and Co values from disparate laterite ores.

IPC Classes  ?

• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
• C22B 23/00 - Obtaining nickel or cobalt
• C22B 3/44 - Treatment or purification of solutions, e.g. obtained by leaching by chemical processes
• C22B 3/22 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means
• C01F 5/24 - Magnesium carbonates
• C01G 49/00 - Compounds of iron

Abstract

Functional food comprising montbretin A and use of the functional food for limiting polysaccharide processing in a human subject and for treating conditions treatable by inhibiting pancreatic a-amylase.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A21D 2/14 - Organic oxygen compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A method of separating actinium and/or radium from proton-irradiated thorium metal. The thorium metal is irradiated to produce isotopes including thorium, actinium and/or radium. The resultant product is dissolved in solution and a selective precipitant is used to precipitate a bulk portion of the thorium. The precipitated thorium can be recovered. Chromatography is carried out on the remaining solution to remove residual thorium and to separate the actinium from the radium.

IPC Classes  ?

• G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
• C01F 17/13 - Preparation or treatment, e.g. separation or purification by using ion exchange resins, e.g. chelate resins
• B01D 15/18 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
• B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
• C01B 15/047 - Metal peroxides or peroxyhydrates thereof; Superoxides; Ozonides of heavy metals
• G21G 1/10 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes outside of nuclear reactors or particle accelerators by bombardment with electrically-charged particles

Abstract

The present invention provides a method of epitope-based vaccine design. The method comprising: a) providing one or more target amino acid sequence(s); b) optionally discarding peptides based on one or more predetermined features; c) parsing and selecting MHC I and/or MHC II binding peptides from said sequences; and d) assembling the MHC I and/or MHC II binding peptides optionally with linkers to produce an assembly of peptides.

IPC Classes  ?

• G16B 35/20 - Screening of libraries
• G16B 20/40 - Population genetics; Linkage disequilibrium
• G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

Provided herein are formulations for spray freeze drying to encapsulate active ingredients, methods of preparing a composition of spray freeze dried micro-particles from the formulations described herein, and micro-particle compositions. In particular, the micro-particle compositions may be for use in the treatment or prophylaxis of a respiratory virus. The respiratory virus may be a coronavirus. In particular, the coronavirus infection may be selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus-1 (SARS-CoV-1) infection; SARS coronavirus-2 (SARS-CoV-2) infection; and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) infection. More specifically, the coronavirus infection may be a human coronavirus 229E (HCoV-229E) infection. The active ingredients may include a protein or a fragment thereof, may be an angiotensin converting enzyme 2 (ACE2) or a fragment thereof. The protein encapsulating micro-particle composition may be used for the delivery of therapeutic proteins to the nasal mucosa.

IPC Classes  ?

• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/50 - Microcapsules
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 31/12 - Antivirals
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 9/98 - Preparation of granular or free-flowing enzyme compositions

Abstract

A method of providing an authenticator for an event includes capturing first information of the event, obtaining a first distillation of the first information of the event. The method also includes digitally signing the first distillation of the information of the event to provide a digitally signed first distillation, and providing the digitally signed first distillation during the event for embedding into the event. The method may include obtaining a recording of the event including a digital signature and a purported first distillation, generating a second distillation of information from the second recording, authenticating the purported first distillation of information utilizing a public key associated with the private key utilized to create the digital signature, and conducting a comparison of the second distillation of the event to the purported first distillation.

IPC Classes  ?

• H04L 9/08 - Key distribution
• H04L 9/30 - Public key, i.e. encryption algorithm being computationally infeasible to invert and users' encryption keys not requiring secrecy
• H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system

Abstract

Clinical detection or diagnosis of transplant rejection currently utilizes various methods that rely on qualitative rather than quantitative data, or quantitative data that has low sensitivity and/or has a high rate of operator error. Provided herein are methods for identifying kidney transplant rejection in patents that is automated and consistent for the user. Further described herein are cut-offs for transplant biomarkers that relate to renal transplantation stability or rejection.

IPC Classes  ?

• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Apparatus for monitoring a pose of a tool relative to an object includes plural range sensors arranged on a support. The range sensors may be provided by plural ultrasound transducers. The support is integrated with or coupled to: the tool. The tool may comprise a guide configured to constrain another tool to be moved along an axis defined by the guide. The transducers output signals that encode plural measured distances between points having known locations relative to the support and points on a surface of the object. A data processing system is configured to: process the signals to obtain the plural measured distances; and process the measured distances to generate an estimated pose of the support relative to the object. A user feedback interface is operative to communicate to a user information about a current pose of the tool relative to the object. The apparatus has example application in surgery including drilling holes for pedicle screws.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters

Abstract

Helmet prevent or mitigate cervical spine fractures, including the type of injuries associated with axial compression of the spine and fracture of the spine which may otherwise result in deformation and/or injury to the spinal cord. Helmets convert an impact force with a component aligned with the axis of the spine (a “spinally axial component”) to rotational motion. In the event of a head-first impact, such helmets flexion of the neck so that the head and the cervical spine are not aligned (or less aligned) with the direction of an impact force, thereby mitigating the likelihood and/or severity of cervical spine fractures.

IPC Classes  ?

• A42B 3/06 - Impact-absorbing shells, e.g. of crash helmets

Abstract

The present invention provides a method of determining the amount of a psilocybin in a sample, the method comprising contacting a cell which expresses ABCF1 with the sample, comparing the expression of ABCF1 with a standard to determine the amount of psilocybinin in the sample. Also provided are methods of microdosing based on ABCF1 expression.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 25/00 - Drugs for disorders of the nervous system
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/577 - Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies

Abstract

A method for activating minerals using microwaves to enhance the reactivity of the minerals to carbon dioxide.

IPC Classes  ?

• B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
• B01D 53/62 - Carbon oxides
• B01J 20/30 - Processes for preparing, regenerating or reactivating

Abstract

The present disclosure provides a novel lipid nanoparticle (LNP) compositions useful for the transfection and expression of exogenous proteins in platelet cells. In particular, wherein the LNP composition comprises mRNA encoding the exogenous protein and a lipid mixture, and the lipid mixture comprises at least one ionizable cationic lipid, at least one helper lipid, a sterol, and at least one polyethylene glycol (PEG)-lipid conjugate. Further provided are use of the LNP compositions for transfection of platelets with messenger RNA encoding an exogenous protein and expression of the exogenous protein in the resulting transfected platelets.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 9/51 - Nanocapsules
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• C12P 21/00 - Preparation of peptides or proteins
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

Abstract

Methods, systems, and techniques for the contactless operation of capacitive micromachined ultrasonic transducers (CMUTs) and CMUT arrays. Contactless operations refers to both the contactless transfer of energy and information between the transducer(s) and the controlling subsystem. A system includes a CMUT, a first alternating current voltage source, a first inductor electrically coupled to the first voltage source, and a second inductor electrically coupled to the CMUT. The second inductor is physically decoupled from, and positioned to be wirelessly coupled to, the first inductor. A contactless configuration is useful for a wide range of applications, from wearable transducers to high-end ultrasound imaging systems.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy

Abstract

Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/564 - Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present disclosure provides a lipid nanoparticle comprising an siRNA molecule against ADAMTS13, the siRNA molecule containing modified or unmodified nucleotides. Further provided is an siRNA molecule against ADAMTS13, the siRNA molecule containing modified or unmodified nucleotides and is between 15 and 35 nucleotides in length and has at least 80% sequence identity to SEQ ID NOs: 1-10.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/51 - Nanocapsules
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 7/04 - Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is —(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3. R3 is a peptide-bonded glycine, aspartate or glutamate or is glutamate peptide bonded through Cdelta. L is —CH2NH—, —(CH2)2NH—, —(CH2)3NH—, or —(CH2)4NH—. R4 is a radiometal chelator optionally bound by a radiometal. Variable ‘n’ is 1-3. The compounds may be useful for imaging prostate specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer). This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R1 is —(CH2)5CH3 or comprises 2-4 fused benzene rings. R2 is I, Br, F, Cl, H, OH, OCH3, NH2, NO2 or CH3. R3 is a peptide-bonded glycine, aspartate or glutamate or is glutamate peptide bonded through Cdelta. L is —CH2NH—, —(CH2)2NH—, —(CH2)3NH—, or —(CH2)4NH—. R4 is a radiometal chelator optionally bound by a radiometal. Variable ‘n’ is 1-3. The compounds may be useful for imaging prostate specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).

IPC Classes  ?

• C07K 5/02 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
• A61K 51/04 - Organic compounds

Abstract

The present invention relates, in part, to methods for the stratification, prognosis, diagnosis and stratification of a cancer, such as an ovarian cancer or a breast cancer.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/30 - Unsupervised data analysis

Abstract

The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, A-III, A- IV, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

IPC Classes  ?

• C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents
• C07K 1/13 - Labelling of peptides
• C07K 7/02 - Linear peptides containing at least one abnormal peptide link

Abstract

The preparation of amine containing polymers from commodity polyolefins has been achieved through the functionalization of polybutadiene. The pre-functionalized polybutadiene is comprised of butadiene and optionally other monomers such as styrene. The butadiene monomer can be enchained with a mixture of both 1,4- and 1,2- subunits. Amine functionalization of the polybutadiene substrate has been afforded using a single step catalytic reaction termed hydroaminoalkylation (HAA).

IPC Classes  ?

• C08F 236/06 - Butadiene
• C08F 8/32 - Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
• C08G 59/24 - Di-epoxy compounds carbocyclic
• C08G 59/50 - Amines
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• C08K 5/1515 - Three-membered rings
• C08L 47/00 - Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds; Compositions of derivatives of such polymers

Abstract

A metal alloy is provided which includes by weight percentage of the metal alloy, 28 to 55 percent copper, 45 to 63 percent nickel, and 4 to 10 percent iron. The metal alloy may be weight percentage 28 percent copper, 62 percent nickel, and 10 percent iron. The metal alloy may be formed into a foil which may have a thickness of 100 μm or less or 50 μm or less. A magnetic field instrument may include a magnetometer core body formed from one or more layers of the foil. The magnetometer core body may be a ring core or a racetrack core. The magnetic field instrument may further include a sense winding and may further include a drive winding. The magnetic field instrument may be a fluxgate magnetometer.

IPC Classes  ?

• H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
• G01R 33/00 - Arrangements or instruments for measuring magnetic variables

Abstract

The present invention provides vaccines against respiratory viruses including coronavirus, such as SARS-CoV-2, and influenza viruses. In particular, the present invention provides vaccines against SARS-CoV-2 which encode a targeting domain and a SARS-CoV-2 spike protein or fragment thereof.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 31/14 - Antivirals for RNA viruses

Abstract

There is provided peptidic compounds of Formula I, A or B(Rradn6n6-[linker]-RL-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-ψ-Xaa922). Xaa1is D-Phe, Cpa, D-Cpa, Nal, D-Nal, 2-Nal, or D-2-Nal; Xaa2is Asn, Gln, Hse, Cit or His. Xaa3is Trp, Bta, Trp(Me), Trp(7-Me), Trp(6-Me), Trp(5-Me), Trp(4-Me), Trp(2-Me), Trp(7-F), Trp(6-F), Trp(5-F), Trp(4-F), Trp(5-OH), or αMe-Trp. Xaa4is Ala or Ser. Xaa5is Val, Cpg, or Tle. Xaa6is Gly, NMe-Gly, or D-Ala. Xaa7is His or NMe-His. Xaa8is Leu or Phe. Xaa9222Thz, or Thz. ψ represents a peptide bond or reduced peptide bond joining Xaa8to Xaa9.Rradn6n6 is 1-5 radiolabeling groups. There is also provided the use of such compounds as imaging agents or therapeutic agents.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents
• C07K 1/13 - Labelling of peptides
• C07K 14/595 - Gastrins; Cholecystokinins (CCK)
• C07K 14/72 - Receptors; Cell surface antigens; Cell surface determinants for hormones

Abstract

The invention provides biocompatible polyvinyl alcohol (PVA) matrices, composed of blends of differently hydrolyzed PVAs. The PVA matrices may be formed into controlled release formulations, for example for topical drug delivery.

IPC Classes  ?

• C08L 29/04 - Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• A61K 33/38 - Silver; Compounds thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61F 13/00 - Bandages or dressings; Absorbent pads

Abstract

A handle comprises a grip and an ultraviolet radiation emitter operable to emit ultraviolet radiation to disinfect the grip. The grip has a body extending in a longitudinal direction between a proximal end surface located at a proximal end of the grip and a distal end surface located at an opposing distal end of the grip. The ultraviolet radiation emitter is located at the proximal end of the grip and configured to emit ultraviolet radiation. In some embodiments, the ultraviolet radiation emitter is configured to direct ultraviolet radiation from the proximal end and in directions oriented toward the body.

IPC Classes  ?

• A61L 2/10 - Ultraviolet radiation
• A61L 2/26 - Accessories
• E05B 1/00 - Knobs or handles for wings; Knobs, handles, or press buttons for locks or latches on wings

Abstract

Provided herein are Alotaketal compounds and derivatives thereof that have antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (1), (2) and (3), for use as antiviral agents in the treatment or prevention of coronavirus infection. Methods for using the compounds in the treatment or prophylaxis of a coronavirus infection are provided. In particular, the coronavirus infection may selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus- 1 (SARS-C0V-1) infection; SARS coronavirus- 2 (SARS-C0V-2) infection; and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) infection. More specifically, the coronavirus infection may be a human coronavirus 229E (HC0V-229E) infection.

IPC Classes  ?

• C07D 493/10 - Spiro-condensed systems
• A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
• A61P 31/14 - Antivirals for RNA viruses

Abstract

This invention provides the use of specialized proresolving mediators (SPMs) for use as melanocyte growth promoters and pro-survival factors. More particularly, the SPM compositions are suitable for promoting melanocyte growth and/or survival to prevent depigmentation of melanocytes and/or promoting repigmentation in non-inflammatory depigmentation of melanocytes. Furthermore, the compositions may be used to treat dormant vitiligo lesions, chemically induced vitiligo, vitiligo that is non-responsive to inflammatory therapies, or canities.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 17/00 - Drugs for dermatological disorders
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Spatial-sequencing methods are disclosed.

IPC Classes  ?

• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6869 - Methods for sequencing
• C04B 20/04 - Heat treatment
• C40B 70/00 - Tags or labels specially adapted for combinatorial chemistry or libraries, e.g. fluorescent tags or barcodes
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

A chelator having the general structure (I) for chelating ra-diometals such as 225Ac under mild conditions is provided. (I) The chelator can be coupled to a biological targeting moiety to facilitate targeted delivery of the chelated radiometal in a mammalian subject.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
• A61K 51/08 - Peptides, e.g. proteins

Abstract

Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer; lymphoma; neuroblastoma; breast cancer; colon cancer; cervical cancer; small-cell lung carcinoma; osteosarcoma; glioblastoma; melanoma; and myeloid leukaemia.

IPC Classes  ?

• C07C 255/64 - Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/277 - Nitriles; Isonitriles having a ring, e.g. verapamil
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61P 35/00 - Antineoplastic agents
• C07C 311/16 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
• C07C 323/62 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
• C07D 207/323 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
• C07D 207/404 - 2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
• C07D 309/18 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member containing only hydrogen and carbon atoms in addition to the ring hetero atom
• C07D 333/54 - Benzo [b] thiophenes; Hydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 339/06 - Five-membered rings having the hetero atoms in positions 1 and 3, e.g. cyclic dithiocarbonates
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present disclosure provides: reporter systems for CRISPR-mediated gene editing; gRNAs, RNPs, and compositions for the reporter systems; and methods of testing CRISPR-mediated gene editing. The present disclosure further provides compositions and methods for knocking out a DNA segment of interest; and methods of effecting CRISPR-mediated gene editing in the eye. The present disclosure also provides compositions and methods for effecting base editing using base editors.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 38/46 - Hydrolases (3)
• C12N 9/22 - Ribonucleases
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

According to at least one embodiment, methods of fabricating micro electro-mechanical systems (MEMS) structures involving lamination of an electromechanical layer to a micromechanical structure are disclosed.

IPC Classes  ?

• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate
• B81B 7/02 - Microstructural systems containing distinct electrical or optical devices of particular relevance for their function, e.g. microelectro-mechanical systems (MEMS)
• G05B 19/18 - Numerical control (NC), i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
• H01L 41/22 - Processes or apparatus specially adapted for the assembly, manufacture or treatment of piezo-electric or electrostrictive devices or of parts thereof

Abstract

The present disclosure relates to the use of carbonaceous matter and a reagent comprising a thiocarbonyl functional group, for example, in a method for extracting a base metal such as copper from a material comprising the base metal. Such methods can comprise contacting the material under acidic conditions with the carbonaceous matter and the reagent comprising the thiocarbonyl functional group; and optionally recovering the base metal.

IPC Classes  ?

• C22B 15/00 - Obtaining copper
• C25C 1/12 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
• C22B 3/08 - Sulfuric acid
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds

Abstract

This application relates to lipid nanoparticles, which include: a helper lipid and an ionizable lipid, at least one lipid layer surrounding an interior having at least one aqeous portion, an encapsulated inorganic particle, and an agent of interest (e.g. therapeutic, diagnostic, or theranostic agents). The ionizable lipid is present at between 2 mol% and 30 mol% relative to total lipid. The agent of interest is a hydrophilic agent present in the at least one aqueous portion or is a lipophilic agent present in the at least one lipid layer. This application also relates to methods of making the lipid nanoparticle, as well as methods of using the lipid nanoparticle (e.g. for therapy or diagnostics), including using external stimuli (e.g. laser irradiation) to release the agent of interest.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 49/00 - Preparations for testing in vivo
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Abstract

Limit size lipid nanoparticles, methods for using the lipid nanoparticles, and methods and systems for making limit size lipid nanoparticles.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
• A61K 9/107 - Emulsions
• A61K 9/127 - Liposomes
• B01F 23/41 - Emulsifying
• B01F 25/431 - Straight mixing tubes with baffles or obstructions that do not cause substantial pressure drop; Baffles therefor
• B01F 25/433 - Mixing tubes wherein the shape of the tube influences the mixing, e.g. mixing tubes with varying cross-section or provided with inwardly extending profiles
• B01F 33/30 - Micromixers
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 49/00 - Preparations for testing in vivo
• A61J 3/00 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms

Abstract

Apparatuses and methods for performing coupled chemical and electrochemical reactions are disclosed. An electrochemical cell has a first reaction chamber configured to perform a chemical reaction and an anode chamber configured to perform an electrochemical reaction. The first reaction chamber and the anode chamber are separated by a first membrane. The first membrane acts as a cathode of the cell, a hydrogen-selective layer and a catalyst. The first membrane may comprise a layer of palladium or a palladium alloy. An ion exchange membrane separates the first membrane and the anode chamber. The chemical and electrochemical reactions may respectively be hydrogenation and dehydrogenation reactions.

IPC Classes  ?

• C07C 5/09 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of carbon-to-carbon triple bonds to carbon-to-carbon double bonds
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
• C25B 3/23 - Oxidation
• C25B 1/02 - Hydrogen or oxygen
• C25B 15/08 - Supplying or removing reactants or electrolytes; Regeneration of electrolytes
• C25B 13/02 - Diaphragms; Spacing elements characterised by shape or form
• C25B 13/04 - Diaphragms; Spacing elements characterised by the material

Abstract

Pharmaceutical formulations and treatments are provided that make combined use of selected antibiotic cannabinoids with silver-containing medicaments. Therapeutically effective regimens are provided that facilitate positive drug-drug interactions between the cannabinoid and the silver-containing medicament in a subject.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 33/38 - Silver; Compounds thereof
• A61P 31/04 - Antibacterial agents

Abstract

Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 9/127 - Liposomes
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61K 9/14 - Particulate form, e.g. powders
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Procedures for inhibiting hormone receptor activation include administering to a subject in need of hormone receptor inhibition a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions. Procedures for treating prostate cancer or breast cancer include administering to a subject having prostate cancer or breast cancer a compound having a chemical structure of a molecule that, when docked in the PPIase pocket, could disrupt proline-rich loop conformation and interactions.

IPC Classes  ?

• C07D 249/08 - 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods for using compositions comprising a Granzyme B inhibitor and a pharmaceutically acceptable carrier for treating and/or preventing blistering and/or peeling of a skin of a subject are provided. Also provided are methods for using the compositions to improve the healing of a blistered or area of peeled skin of a subject. The compositions can be formulated for oral administration, nasal administration, topical administration, subcorneal administration, intra-epidermal administration, sub-epidermal administration, or for administration by injection.

IPC Classes  ?

• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61P 17/00 - Drugs for dermatological disorders
• C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala

Abstract

Methods and apparatuses for converting metal carbonate salts to metal hydroxides are disclosed. The methods involve electrochemical production of hydrogen ions (H+) for decarbonating the metal carbonate salt to generate metal ions in a chemical compartment of the electrochemical cell. The metal ions are transported to a cathode compartment where they combine with hydroxide (OH-) to form metal hydroxides. The methods and apparatus may be applied to produce calcium hydroxide which may be used as a precursor for cement clinker. In some embodiments electrochemically produced hydrogen and oxygen are burned to produce heat for production of cement clinker.

IPC Classes  ?

• C01F 11/02 - Oxides or hydroxides
• B01D 61/42 - Electrodialysis; Electro-osmosis
• C01B 13/14 - Methods for preparing oxides or hydroxides in general
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water

Abstract

Radiolabeled compounds that target fibroblast activation protein (FAP). The compounds have 1-6 radiolabeling groups and 1-6 FAP-targeting groups, connected by 1-11 linkers. FAP-targeting groups have the structure of Formula (I). R1aand R1b1-61-61-61-6 alkyl. R23222-, -S-, or -O-. R32222. R4is -H, methyl, or ethyl. R5is =O. R6is -C(O)-, -O-C(O)-, or -NH-C(O)-. n4 is 0, 1, 2, or 3. R7 is an 11 to 15-membered aromatic, partially aromatic, or non-aromatic fused tricyclic system, wherein the tricyclic system is optionally contains 1-6 heteroatoms selected from N, O, and/or S, and is optionally substituted. There is also provided the use of such compounds as imaging agents or therapeutic agents. Formula (I).

IPC Classes  ?

• C07F 5/02 - Boron compounds
• A61K 51/04 - Organic compounds
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

Embodiments of the present disclosure relate to apparatus, systems, and methods for detection and differentiation of selected hydrocarbon gases in a target gas composition. The apparatus comprises a sensing unit; a housing comprising a first housing portion and a second housing portion, the first housing portion for receiving a linear actuator, the linear actuator operatively coupleable to the sensing unit proximal to the inlet, and the second housing portion for receiving at least a portion of the inlet end of the sensing unit and comprising at least one chamber and a closure member housed within the second housing portion and adjacent the inlet, the closure member actuatable between a closed state and an open state by the linear actuator; wherein the at least one chamber is in fluid communication with the inlet when the closure member is in the open state.

IPC Classes  ?

• G01M 3/18 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point using electric detection means for valves

Abstract

The present disclosure relates to the use of a wetting agent such as a non-ionic wetting agent and a reagent comprising a thiocarbonyl functional group, for example, in a method/process or use for extracting a base metal such as copper from a material comprising the base metal. Such methods/processes can comprise contacting the material under acidic conditions with the wetting agent and the reagent comprising the thiocarbonyl functional group; and optionally recovering the base metal.

IPC Classes  ?

• C22B 3/08 - Sulfuric acid
• C22B 15/00 - Obtaining copper
• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae

Abstract

Provided herein are systems and methods for determining a subject's risk of spontaneous coronary artery dissection (SCAD) and myocardial infarction (MI) and systems and methods of using SCAD and/or MI risk for treatment thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 31/616 - Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

An apparatus for remote interaction with a patient includes a local system including a physical element to interact with the patient, and a local electronic device with a camera to capture images of the physical element interacting with the patient, and a local display to display the images with a virtual representation of the physical element relative to the patient. The local electronic device obtains information dependent on position and orientation of the physical element interacting with the patient. A remote system includes a remote electronic device with a display to display the images of the physical element interacting with the patient, and an image based on the information. A remote input device controls position and orientation of the virtual representation displayed on the local display. The remote system communicates with the local system with low latency for alignment of the physical element with the virtual representation.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

Disclosed is a peptide including (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Also disclosed is a method of reducing the phosphorylation of TDP-43 in a cell, the method including: delivering an effective amount of a peptide to the cell, wherein the peptide comprises: (a) a cell membrane penetration (CMP) sequence; and (b) a TDP-43 phosphorylation-blocking (PB) sequence. Also disclosed is a method of treating a disease or pathological condition, the method comprising administering an effective amount of a peptide to a subject in need thereof; wherein the peptide comprises: (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Related uses, peptides for use, vectors, polynucleotide, and pharmaceutical compositions are disclosed.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

Mycobacterial antigens, such as MAP and M. bovis antigens, are described. The antigens can be used in subunit compositions to elicit immune responses in order to prevent and/or control mycobacterial infections, as well as in diagnostics in order to detect mammals infected with mycobacteria.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/04 - Antibacterial agents
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A method for thermal cracking of a hydrocarbon to produce hydrogen gas and carbon comprises heating a molten medium to an operating temperature sufficient to thermally crack the hydrocarbon. The operating temperature may, for example be in the range of 600° C. to 1100° C. The method mixes the hydrocarbon into the heated molten medium and pumping the mixed molten medium and hydrocarbon through a reactor. In the reactor, the hydrocarbon undergoes a thermal cracking reaction which forms hydrogen gas and carbon black. The method separates the carbon and hydrogen gas from the molten medium that has passed through the reactor. In some embodiments, the flow of the molten medium in the reactor is a turbulent flow.

IPC Classes  ?

• C01B 3/26 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of gaseous or liquid organic compounds of hydrocarbons using catalysts
• B01J 35/12 - Liquids or melts
• B01J 10/00 - Chemical processes in general for reacting liquid with gaseous media other than in the presence of solid particles; Apparatus specially adapted therefor
• B01J 19/24 - Stationary reactors without moving elements inside
• B01J 8/08 - Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with moving particles

Abstract

The present invention provides methods of treating cancer by modulating regulators of IL-33. Also provided are methods of preventing tumor metastasis and/or cancer progression by treatment with agents that modulate FOX1A. Also provided are diagnostic methods for assessing cancer prognosis.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

Example methods and apparatus for creating a reaction product. An example method comprises flowing a first fluid in a flow direction in a first conduit in a multilayer extrusion reactor apparatus. The first fluid may be characterized by inertial forces dominating viscous forces of the first fluid. The method flows a second fluid in a flow direction in a second conduit in the apparatus. The first and second fluids may be miscible with one another. The method shapes the first and second conduits to provide an interface region between the first and second fluids. The method permits a reaction to create a reaction product in the interface region. The reaction product may mitigate flow-disrupting mixing between the first and second fluids.

IPC Classes  ?

• B29C 48/16 - Articles comprising two or more components, e.g. co-extruded layers
• B29C 48/08 - Flat, e.g. panels flexible, e.g. films

Abstract

A method of simulating a quantum computation is provided. The method includes determining, by a first system (110) including one r more first processing units (112), a size parameter of a quantum computation. The quantum computation is configured for solving a computational problem. The size parameter is characteristic of an input size of the computational problem. The method includes communicating, by the first system, the size parameter to a second system (120) including one or more second processing units (122). The method includes communicating, by the second system, a computational key to the first system, wherein the computational key is based on the size parameter of the quantum computation. The method includes performing, by the first system, a simulation of the quantum computation based on the computational key.

IPC Classes  ?

• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms

Abstract

Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of L-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

A reactor that operates with ultraviolet light emitting diodes (UV-LEDs) to attain UV photoreactions or UV photo-initiated reaction in a fluid flow for various applications, including water purification. The UV-LED reactor is comprised of a conduit means for passing fluid flow, an ultraviolet light emitting diode (UV-LED), and a radiation-focusing element to focus the UV-LED radiation to the fluid in the longitudinal direction of the conduit. The UV-LED reactor may include photocatalysts or chemical oxidants, which are activated by UV emitted by UV-LEDs for photocatalytic and photo-initiated reactions.

IPC Classes  ?

• C02F 1/32 - Treatment of water, waste water, or sewage by irradiation with ultraviolet light
• C02F 1/72 - Treatment of water, waste water, or sewage by oxidation

Abstract

Particles of a carbonate compound, such as calcium carbonate, in an amorphous form may be precipitated from solution, freeze dried and compressed to form transparent or translucent objects. The objects may, for example comprise blocks, bricks or other shapes that may be used in construction of buildings. Advantageously the carbonate compound may incorporate carbonate ions obtained by capture of carbon dioxide from an atmosphere of air, flue gas, exhaust gas or the like. Captured carbon may be sequestered in the objects indefinitely.

IPC Classes  ?

• C09C 1/02 - Compounds of alkaline earth metals or magnesium
• A62D 3/33 - Processes for making harmful chemical substances harmless, or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by chemically fixing the harmful substance, e.g. by chelation or complexation
• B01D 53/62 - Carbon oxides
• C04B 14/28 - Carbonates of calcium
• C04B 20/10 - Coating or impregnating

Abstract

A method of moving materials comprises: flowing a first fluid in an axial direction, the first fluid characterized by inertial forces dominating viscous forces of the first fluid; flowing a second fluid in the axial direction, the first and second fluids miscible with one another and the first and second fluids having an interface region therebetween; permitting a reaction to create a reaction product in the interface region, the reaction product mitigating flow-disrupting mixing between the first and second fluids.

IPC Classes  ?

• B29C 64/321 - Feeding
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 40/00 - Auxiliary operations or equipment, e.g. for material handling

Abstract

An apparatus for collecting a gas sample may include a cartridge fluidly connected to the gas sample at a first end of the cartridge, the cartridge having: one or more bores; and sample media in the one or more bores, and a pressure source capable of drawing the gas sample through the apparatus. In some embodiments, the apparatus may further comprise: a conduit with a first end fluidly connected to the gas sample and a second end opposite to the first end connected to the cartridge. The conduit further comprises an interface that fluidly connects the gas sample to the first end of the conduit, and one or more sensors capable of measuring one or more parameters of the gas sample within the conduit.

IPC Classes  ?

• G01N 1/22 - Devices for withdrawing samples in the gaseous state
• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• G01N 1/24 - Suction devices
• G01N 1/40 - Concentrating samples
• G01F 15/06 - Indicating or recording devices

Abstract

Apparatuses and methods for producing hydrogen peroxide by performing coupled chemical and electrochemical reactions are disclosed. An electrochemical cell has a chemical reaction chamber configured to hydrogenate a shuttle molecule and an electrochemical chamber configured to electrochemically dissociate water to form hydrogen ions at an anode, and to reduce the hydrogen ions to atomic hydrogen at a cathode. The chemical reaction chamber and the anode chamber are separated by a metallic membrane. The metallic membrane acts as a cathode of the cell, a hydrogen-selective layer and a catalyst. The metallic membrane may comprise a layer of palladium or a palladium alloy. A layer of co-catalyst may optionally be electrodeposited on the layer of palladium or palladium alloy. An ion exchange membrane separates the metallic membrane and the anode chamber. The hydrogenated shuttle molecule may be supplied to a reactor for contacting an oxygen-containing gas to yield hydrogen peroxide.

IPC Classes  ?

• C25B 15/08 - Supplying or removing reactants or electrolytes; Regeneration of electrolytes
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
• C01B 15/029 - Preparation from hydrogen and oxygen
• C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
• C25B 11/052 - Electrodes comprising one or more electrocatalytic coatings on a substrate
• B01D 71/02 - Inorganic material

Abstract

Provided herein are compounds that inhibit glycogen synthase kinase-3 (GSK3) giving them antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (I) and (II), for use as antiviral agents in the treatment or prevention of viral infection. Methods for using the GSK3 inhibitor compounds in the treatment or prophylaxis of a viral infection are provided. In particular, the viral infection may be selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus- 1 SARS-CoV-1) infection; SARS coronavirus-2 (SARS-CoV-2) infection; and Middle East Respiratory Syndrome (MFRS) coronavirus (MERS-CoV) infection. More specifically, the viral infection may be a human coronavirus 229E (HCoV-229E) infection.

IPC Classes  ?

• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/4245 - Oxadiazoles
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The disclosure pertains to single chain antibodies, nucleic acids and vectors that encode antibodies that for example specifically bind W68 in the context of DAGWGNL (SEQ ID NO: 1) and methods of administering the single chain antibodies, nucleic acids and vectors to a subject in need thereof.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The present disclosure relates to amatoxin analogs comprising one or more modifications of eastern ring residues, constructs comprising such amatoxin analogs coupled to a linker and conjugates comprising such amatoxin analogs or compound-linker constructs. The present disclosure also relates to uses of such amatoxin analogs, for example, in treatment of cancer. For example, the amatoxin analog can be a compound of Formula (I).

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/12 - Cyclic peptides
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 35/00 - Antineoplastic agents
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
• C07K 19/00 - Hybrid peptides

Abstract

The present disclosure provides a lipid nanoparticle comprising an siRNA molecule against fibrinogen alpha chain, the siRNA molecule containing modified or unmodified nucleotides. Further provided is an siRNA molecule against fibrinogen alpha chain, the siRNA molecule containing modified or unmodified nucleotides and is between 15 and 35 nucleotides in length and has at least 80% sequence identity to SEQ ID NOs: 1-10.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/51 - Nanocapsules
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present disclosure provides a lipid nanoparticle comprising an siRNA molecule against fibrinogen alpha chain, the siRNA molecule containing modified or unmodified nucleotides. Further provided is an siRNA molecule against fibrinogen alpha chain, the siRNA molecule containing modified or unmodified nucleotides and is between 15 and 35 nucleotides in length and has at least 80% sequence identity to SEQ ID NOs: 1-10.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/51 - Nanocapsules
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

A composite structure comprising a hydrophobic coating that is in contact with an aqueous environment is disclosed. The coating comprises a first layer that comprises an amine functionalized polymer layer with a thickness of 1 to 500 micrometers and a second layer that comprises a fluoropolymer, a polyolefin or a combination thereof; and methods of making and repairing said composite structure. The composite adhesives which can be applied as a paint to a surface. These superhydrophobic surfaces are useful for a variety of applications drag reduction, as an anti-fouling surface in marine engineering, and as sealants and gaskets in static applications.

IPC Classes  ?

• C09J 7/30 - Adhesives in the form of films or foils characterised by the adhesive composition
• C08J 7/043 - Improving the adhesiveness of the coatings per se, e.g. forming primers
• C09J 7/24 - Plastics; Metallised plastics based on macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
• C09J 201/02 - Adhesives based on unspecified macromolecular compounds characterised by the presence of specified groups
• C09D 5/16 - Anti-fouling paints; Underwater paints

Abstract

The present disclosure relates to the use of antiviral agents that are cladoniamides and derivatives thereof such as the compound Formula I, for example, for the treatment of viral infections such as those caused by coronaviruses and/or flaviviruses. The present disclosure also includes antiviral agents and methods for their preparation. (I) The present disclosure relates to the use of antiviral agents that are cladoniamides and derivatives thereof such as the compound Formula I, for example, for the treatment of viral infections such as those caused by coronaviruses and/or flaviviruses. The present disclosure also includes antiviral agents and methods for their preparation. (I)

IPC Classes  ?

• C07D 471/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups in which the condensed systems contains four or more hetero rings
• A61P 31/14 - Antivirals for RNA viruses

Abstract

An integrated optical linewidth reduction system based on optical feedback and a low-speed electronic control loop to control the optical feedback. Light is tapped and reflected back to the laser with an amplitude, phase or both amplitude and phase adjustment such that the linewidth of the laser is lower than the free-running laser linewidth. The amplitude of the feedback signal may be controlled using an optical attenuator. The phase of the feedback signal may be controlled using a phase shifter. The amplitude of the optical feedback may be monitored by means of a filter and a photodetector, or just a photodetector. The amplitude and/or phase of the optical feedback is monitored by means of a frequency/phase noise discriminator. The phase shifter can be an endless phase shifter

IPC Classes  ?

• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• H01S 3/106 - Controlling the intensity, frequency, phase, polarisation or direction of the emitted radiation, e.g. switching, gating, modulating or demodulating by controlling devices placed within the cavity
• H01S 3/086 - One or more reflectors having variable properties or positions for initial adjustment of the resonator